Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Injectable cabotegravir and rilpivirine are approved for people with viral suppression who would prefer monthly injections to daily pills.
A study analyzed how well people with HIV and their health care providers can navigate the experimental long-acting injectable Cabenuva.
After years of taking daily oral cabotegravir and Edurant, people with suppressed HIV switched to long-acting injectable Cabenuva.
4% of total U.S. AIDS philanthropy directly addresses African Americans. Plus: Meet the top five funders helping BIPOC communities.
A global study examined how outcomes improve when physicians engage their HIV-positive patients in joint decision-making.
A clinical trial compared injectable cabotegravir given every eight weeks versus daily Truvada for HIV prevention.
“As Much As I Can” returns with a new format but the same powerful messages.
Who got what and why? NMAC’s Paul Kawata addresses criticism and breaks down the data.
The trial will investigate whether injections of long-acting cabotegravir and rilpivirine yield a superior rate of viral suppression.
A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)
“As Much As I Can” debuted in the South. This week, it opens in Harlem, New York.
“As Much As I Can” is part of the Accelerate! initiative. Tickets are free!
ViiV Healthcare’s four-year, $10 million ’Accelerate!’ initiative aims to reduce the HIV epidemic among black men who have sex with men (MSM)...
ViiV Healthcare has given about $ 6 million to 99 projects in 26 countries to improve the health of women, children and families affected by H...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.